Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch(University Hospital of Bern), Zoltán Kutalik(University of Lausanne), Patrick Descombes(University of Geneva), Tao Cai(University of Lausanne), Julia di Iulio(University of Lausanne), Tobias Mueller(Charité - Universitätsmedizin Berlin), Murielle Bochud(University of Lausanne), Manuel Battegay(University Hospital of Basel), Enos Bernasconi(Ospedale regionale di Lugano), Jan Borovicka(University of St. Gallen), Sara Colombo(University of Lausanne), Andreas Cerny(Clinica Luganese Moncucco), Jean‐François Dufour(University Hospital of Bern), Hansjakob Furrer(University Hospital of Bern), Huldrych F. Günthard(University of Zurich), Markus H. Heim(University Hospital of Basel), Bernard Hirschel(University Hospital of Geneva), Raffaele Malinverni(Hospital Neuchâtel), Darius Moradpour, Beat Müllhaupt(University Hospital of Zurich), Andrea Witteck(University of St. Gallen), J. Beckmann(University Hospital of Lausanne), Thomas Berg(Charité - Universitätsmedizin Berlin), Sven Bergmann(University of Lausanne), Francesco Negro(University Hospital of Geneva), Amalio Telenti(University of Lausanne), Pierre–Yves Bochud(University of Lausanne)
Cited by 1,133
Abstract
Related Papers
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al.|New England Journal of Medicine|2002|6.4k
Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
Raymond T. Chung, Janet Andersen, Paul A. Volberding et al.|New England Journal of Medicine|2004|873